^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    TheraCys (PMCJ-9)

    i
    Other names: PMCJ-9, BCG bladder cancer vaccine
    Associations

    News

    Trials
    Company:
    Sanofi
    Drug class:
    Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    over1year
    A Clinical Study of V940 and BCG in People With Bladder Cancer (V940-011/INTerpath-011) (clinicaltrials.gov)
    P2, N=308, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting
    Enrollment open
    |
    intismeran autogene (mRNA-4157) • TheraCys (PMCJ-9)
    over1year
    A Clinical Study of V940 and BCG in People With Bladder Cancer (V940-011/INTerpath-011) (clinicaltrials.gov)
    P2, N=308, Not yet recruiting, Merck Sharp & Dohme LLC
    New P2 trial
    |
    intismeran autogene (mRNA-4157) • TheraCys (PMCJ-9)
    3years
    BCG+MMC: Adding Mitomycin to BCG as Adjuvant Intravesical Therapy for High-risk Non-Muscle-invasive Bladder Cancer (clinicaltrials.gov)
    P3, N=501, Active, not recruiting, University of Sydney | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    mitomycin • TheraCys (PMCJ-9) • Tice BCG (live attenuated bacillus Calmette-Guerin)
    5years
    Electromotive Mitomycin-C (EMDA-MMC) in Preventing Recurrences in High-risk Non-muscle-invasive Bladder Cancer (clinicaltrials.gov)
    P3, N=300, Recruiting, Turku University Hospital | Trial primary completion date: Nov 2023 --> Nov 2025
    Trial primary completion date
    |
    mitomycin • TheraCys (PMCJ-9) • Tice BCG (live attenuated bacillus Calmette-Guerin)
    7years
    Electromotive Mitomycin-C (EMDA-MMC) in Preventing Recurrences in High-risk Non-muscle-invasive Bladder Cancer (clinicaltrials.gov)
    P3, N=300, Recruiting, Turku University Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    mitomycin • TheraCys (PMCJ-9) • Tice BCG (live attenuated bacillus Calmette-Guerin)
    almost8years
    Electromotive Mitomycin-C (EMDA-MMC) in Preventing Recurrences in High-risk Non-muscle-invasive Bladder Cancer (clinicaltrials.gov)
    P3, N=300, Not yet recruiting, Turku University Hospital
    New P3 trial
    |
    mitomycin • TheraCys (PMCJ-9) • Tice BCG (live attenuated bacillus Calmette-Guerin)